ImmunityBio (IBRX) Facing Lawsuit After FDA Flags Misleading Cancer Claims, Shares Plunge 21%, $2B Market Cap Lost -- HBSS

IBRX Investors with Losses Encouraged to Contact the Firm Before May 26th Deadline SAN FRANCISCO, May 23, 2026 /PRNewswire/ -- ImmunityBio, Inc. (NASDAQ: IBRX) faces a securities class action lawsuit which seeks to represent investors who purchased or otherwise acquired ImmunityBio...